Literature DB >> 25156384

An in silico protocol for identifying mTOR inhibitors from natural products.

Lei Chen1, Ling Wang, Qiong Gu, Jun Xu.   

Abstract

The mammalian target of rapamycin (mTOR) is an anti-cancer target. In this study, we propose an in silico protocol for identifying mTOR inhibitors from the ZINC natural product database. First, a three-dimensional quantitative structure-activity relationship pharmacophore model was built based on known mTOR inhibitors. The model was validated with an external test set, Fischer's randomization method, a decoy set and pharmacophore mapping conformation testing. The results showed that the model can predict the mTOR inhibition activity of the tested compounds. Virtual screening was performed based on the best pharmacophore model, and the results were then filtered using a molecular docking approach. In addition, molecular mechanics/generalized born surface area analysis was used to refine the selected candidates. The top 20 natural products were selected as potential mTOR inhibitors, and their structural scaffolds could serve as building blocks in designing drug-like molecules for mTOR inhibition.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25156384     DOI: 10.1007/s11030-014-9543-5

Source DB:  PubMed          Journal:  Mol Divers        ISSN: 1381-1991            Impact factor:   2.943


  32 in total

1.  How to optimize shape-based virtual screening: choosing the right query and including chemical information.

Authors:  Johannes Kirchmair; Simona Distinto; Patrick Markt; Daniela Schuster; Gudrun M Spitzer; Klaus R Liedl; Gerhard Wolber
Journal:  J Chem Inf Model       Date:  2009-03       Impact factor: 4.956

Review 2.  Targeting the EGFR and the PKB pathway in cancer.

Authors:  Shoshana Klein; Alexander Levitzki
Journal:  Curr Opin Cell Biol       Date:  2009-02-11       Impact factor: 8.382

3.  Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation.

Authors:  Andrew Y Choo; Sang-Oh Yoon; Sang Gyun Kim; Philippe P Roux; John Blenis
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-27       Impact factor: 11.205

4.  Molecular dynamics-based virtual screening: accelerating the drug discovery process by high-performance computing.

Authors:  Hu Ge; Yu Wang; Chanjuan Li; Nanhao Chen; Yufang Xie; Mengyan Xu; Yingyan He; Xinchun Gu; Ruibo Wu; Qiong Gu; Liang Zeng; Jun Xu
Journal:  J Chem Inf Model       Date:  2013-09-18       Impact factor: 4.956

5.  3D QSAR pharmacophore based virtual screening and molecular docking for identification of potential HSP90 inhibitors.

Authors:  Sugunadevi Sakkiah; Sundarapandian Thangapandian; Shalini John; Yong Jung Kwon; Keun Woo Lee
Journal:  Eur J Med Chem       Date:  2010-02-04       Impact factor: 6.514

Review 6.  Current development of mTOR inhibitors as anticancer agents.

Authors:  Sandrine Faivre; Guido Kroemer; Eric Raymond
Journal:  Nat Rev Drug Discov       Date:  2006-08       Impact factor: 84.694

7.  A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma.

Authors:  Qi-Wen Fan; Zachary A Knight; David D Goldenberg; Wei Yu; Keith E Mostov; David Stokoe; Kevan M Shokat; William A Weiss
Journal:  Cancer Cell       Date:  2006-05       Impact factor: 31.743

8.  Discovery of potent ligands for estrogen receptor beta by structure-based virtual screening.

Authors:  Jie Shen; Chengfang Tan; Yanyan Zhang; Xi Li; Weihua Li; Jin Huang; Xu Shen; Yun Tang
Journal:  J Med Chem       Date:  2010-07-22       Impact factor: 7.446

9.  ATP-competitive inhibitors of the mammalian target of rapamycin: design and synthesis of highly potent and selective pyrazolopyrimidines.

Authors:  Arie Zask; Jeroen C Verheijen; Kevin Curran; Joshua Kaplan; David J Richard; Pawel Nowak; David J Malwitz; Natasja Brooijmans; Joel Bard; Kristine Svenson; Judy Lucas; Lourdes Toral-Barza; Wei-Guo Zhang; Irwin Hollander; James J Gibbons; Robert T Abraham; Semiramis Ayral-Kaloustian; Tarek S Mansour; Ker Yu
Journal:  J Med Chem       Date:  2009-08-27       Impact factor: 7.446

Review 10.  mTOR signaling: implications for cancer and anticancer therapy.

Authors:  E Petroulakis; Y Mamane; O Le Bacquer; D Shahbazian; N Sonenberg
Journal:  Br J Cancer       Date:  2006-01-30       Impact factor: 7.640

View more
  5 in total

1.  Discovering new PI3Kα inhibitors with a strategy of combining ligand-based and structure-based virtual screening.

Authors:  Miao Yu; Qiong Gu; Jun Xu
Journal:  J Comput Aided Mol Des       Date:  2018-01-06       Impact factor: 3.686

2.  Structure-activity relationships study of mTOR kinase inhibition using QSAR and structure-based drug design approaches.

Authors:  Wiame Lakhlili; Abdelaziz Yasri; Azeddine Ibrahimi
Journal:  Onco Targets Ther       Date:  2016-12-02       Impact factor: 4.147

3.  Identification of Potent Chloride Intracellular Channel Protein 1 Inhibitors from Traditional Chinese Medicine through Structure-Based Virtual Screening and Molecular Dynamics Analysis.

Authors:  Wei Wang; Minghui Wan; Dongjiang Liao; Guilin Peng; Xin Xu; Weiqiang Yin; Guixin Guo; Funeng Jiang; Weide Zhong; Jianxing He
Journal:  Biomed Res Int       Date:  2017-09-25       Impact factor: 3.411

4.  Machine Learning Enables Accurate and Rapid Prediction of Active Molecules Against Breast Cancer Cells.

Authors:  Shuyun He; Duancheng Zhao; Yanle Ling; Hanxuan Cai; Yike Cai; Jiquan Zhang; Ling Wang
Journal:  Front Pharmacol       Date:  2021-12-17       Impact factor: 5.810

5.  Marine-Derived Natural Products as ATP-Competitive mTOR Kinase Inhibitors for Cancer Therapeutics.

Authors:  Shraddha Parate; Vikas Kumar; Gihwan Lee; Shailima Rampogu; Jong Chan Hong; Keun Woo Lee
Journal:  Pharmaceuticals (Basel)       Date:  2021-03-21
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.